voriconazole pharmacokinetics and therapeutic drug monitoring

We developed an evidence-based practice guideline for VRZ-individualized medication, which provided comprehensive … Voriconazole is a new-generation triazole antifungal drug with broad-spectrum activity including against Aspergillus spp. Voriconazole is a triazole antifungal medication with expanded antifungal activity including Aspergillus spp. Voriconazole is a first-line agent for the treatment of invasive aspergillosis, invasive candidiasis caused by Candida spp. Methods: There has been an increase in TDM practices for antifungal agents , especially with voriconazole . Voriconazole (VRCZ) is an antifungal triazole recommended as an effective first-line agent for treating invasive aspergillosis. Immunocompromised children are at significant risk of invasive fungal infections (IFIs). Although Therapeutic Drug Monitoring (TDM) of voriconazole is recommended, it remains unknown if TDM-based dose adaptations result in target attainment. 4-8 These pharmacokinetic variabilities have important implications for dosage adjustment because of unpredictable changes in drug exposure, and therapeutic drug monitoring (TDM) using trough samples is recommended in children receiving voriconazole to ensure that doses equivalent to those with demonstrated efficacy, safety and tolerability in adults are delivered. Voriconazole pharmacokinetics were studied in an anuric critically ill patient, under high-volume continuous venovenous hemofiltration, over an interval period after a 4-mg/kg dose of voriconazole. The aim of this study was to investigate the pharmacokinetic variability of VRC and MVRC p … Bottlenose dolphins (Tursiops truncatus), in this article referred to as “dolphins,” in human care can suffer from fungal infections, for example, Candida and Aspergillus species. 1, 2 Isavuconazole is … Voriconazole pharmacokinetics are complex and nonlinear: a saturable clearance (due to saturable hepatic metabolism) has been observed in children receiving drug dose higher than recommended. Large interindividual and intraindividual variability in drug exposure have been reported 6. with reduced susceptibility to fluconazole, and serious infections caused by Scedosporium or Fusarium spp. Voriconazole is a first-line agent in the treatment of many invasive fungal infections and is known to display highly variable pharmacokinetics. The aim of this study was the development and validation of a high performance liquid chromatography (HPLC) method for measuring voriconazole in human serum, and comparison with an ARK immunoassay method. We reviewed the pharmacokinetic and pharmacodynamic characteristics of voriconazole and posaconazole in the context of clinical indications for therapeutic drug monitoring. The indication for voriconazole administration was aspergillosis treatment (74.6%) and prophylaxis (14%). Given high risk of mortality for invasive fungal disease and the inter- and intra-patient variability in posaconazole and voriconazole pharmacokinetics, therapeutic drug monitoring (TDM) is a strategy employed to optimize drug therapy. Background: Therapeutic drug monitoring (TDM) aims to minimize the clinical impact of posaconazole and voriconazole pharmacokinetic variability. 1, 2 These criteria are largely met by the triazole antifungal agents itraconazole, posaconazole, and voriconazole. A population PK model was developed. Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Previous studies of voriconazole therapeutic drug monitoring (TDM) have suggested concentration monitoring to be clinically useful but have been limited by small patient samples at a single institution. Voriconazole is a first-line agent in the treatment of many invasive fungal infections and is known to display highly variable pharmacokinetics. In this article, we review factors influencing voriconazole pharmacokinetic profile, the data supporting exposure-effect and exposure-toxicity relationships, review the gaps in current knowledge, which make broad recommendations for therapeutic drug monitoring difficult for voriconazole, provide the indications in which therapeutic drug monitoring is reasonable based on currently available data (eg, … Antimicrob Agents Chemother. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Therapeutic drug monitoring (TDM), an established practice for many antimicrobials, has recently seen increasing utilization in the management of patients receiving antifungal agents. Favorable responses were observed in 10/10 patients with concentrations above 2.05 μg/ml, while disease progressed in 44% ( n = 18) of patients with concentrations below 2.05 μg/ml. Voriconazole exhibits a narrow therapeutic index, non-linear pharmacokinetics, marked genotypic variability in CYP2C19 metabolizer status and a high propensity for drug-drug interactions [5,26]. Few data are available regarding disposition of the main VRC metabolite (MVRC; UK121,265). Voriconazole is a first-line agent in the treatment of many invasive fungal infections and is known to display highly variable pharmacokinetics. A multidisciplinary approach-for instance by means of antifungal stewardship-will probably be able to overcome problems encountered such as timing of sampling, incompleteness of data in clinical context, and lack of implementation of … Voriconazole is a second generation triazole antifungal agent and the first choice therapy for invasive aspergillosis (IA). Objectives: To develop a population pharmacokinetic model of VRCZ and trough concentration-based dosing simulation for dynamic patient conditions. Azoles exert their effect by inhibition of the fungal cytochrome P450 51p (CYP51p) enzyme resulting in an inhibition of the ergosterol synthesis, an important component of fungal cell membranes.1,–4 In humans, Voriconazole pharmacokinetics are complex and nonlinear: a saturable clearance (due to saturable hepatic metabolism) has been observed in children receiving drug dose higher than recommended. Voriconazole is an expanded‐spectrum triazole used frequently for prophylaxis and treatment of invasive aspergillosis (IA) in patients with haematological malignancies. A probability of target attainment ≥90% was considered optimal. Therapeutic drug monitoring (TDM) aims to minimize the clinical impact of posaconazole and voriconazole pharmacokinetic variability. However, its benefits on clinical outcomes are still being defined. The main reasons for voriconazole trough drug monitoring were initiation of treatment/prophylaxis (33%), patient monitoring (47%), and suspected toxicity (3.5%). Previous studies of voriconazole therapeutic drug monitoring (TDM) have suggested concentration monitoring to be clinically useful but have been limited by small patient samples at a single institution. Therapeutic drug monitoring may play an important role in voriconazole treatment and prophylaxis management. In patients receiving oral voriconazole, a positive correlation was found between trough concentration and drug dose. Voriconazole represents an essential part of antimicrobial therapy in critically ill patients. Arterial and effluent voriconazole concentrations were measured after liquid phase extraction using a high-pressure liquid chromatography. Voriconazole is a triazole antifungal with broad-spectrum activity against yeasts and moulds.1 Therapeutic drug monitoring (TDM) is necessary for all pediatric patients receiving voriconazole due to various reasons including pharmacokinetic variability and CYP2C19 gene polymorphisms (1-3). CONCLUSIONS: The performance of voriconazole therapeutic drug monitoring can still be improved although voriconazole concentrations were monitored in most patients. 1-3 Owing to its non‐linear pharmacokinetics, therapeutic drug monitoring of voriconazole is recommended for optimal safety and efficacy. Voriconazole, an azole antifungal, is commonly used to treat these infections. The pharmacodynamic target was defined as fAUC0–24/0.7. This article is published with Keywords Guideline Voriconazole Therapeutic drug monitoring Introduction Voriconazole (VRCZ) is a triazole antifungal developed for the treatment of fungal infectious disease and is avail- able for both oral and intravenous administration. Voriconazole is a first-line agent in the treatment of many invasive fungal infections and is known to display highly variable pharmacokinetics. Aouri M, Decosterd LA, Buclin T, Hirschel B, Calmy A, Livio F: Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. Therapeutic drug monitoring (TDM) of voriconazole is recommended to optimise clinical results. 57 Voriconazole may potentially be used in combination with other antifungal agents for the treatment … However, its … Antimicrob Agents Chemother 2012, 56(9):4793–4799. We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. • Voriconazole C min for the standard dose was 6.95 ± 3.42 mg/l in cirrhosis patients.. Voriconazole C min was 4.02 ± 2.00 mg/l in cirrhosis patients receiving the halved dose.. Voriconazole C min was related to INR and CYP2C19 inhibitor use in cirrhosis patients. There is a growing body of literature supporting the use of TDM for itraconazole, voriconazole, posaconazole, and … Given the association between CYP2C19 genotype and voriconazole concentrations, as well as the association between voriconazole concentrations and clinical outcomes, particularly efficacy, it seems reasonable to suggest a potential role for CYP2C19 genotype to guide initial voriconazole dose selection followed by therapeutic drug monitoring to increase the probability of achieving efficacy while avoiding … Three oral voriconazole-dosing regimens were simulated: 200, 300, and 400 mg twice daily. Previous studies of voriconazole therapeutic drug monitoring (TDM) have suggested concentration monitoring to be clinically useful but have been limited by small patient samples at a single institution. CYP2C19 genotype represents the main part of the interpersonal variability related to voriconazole blood concentrations. Voriconazole has a high degree of interpatient variability, and some data are suggestive that therapeutic drug monitoring may improve voriconazole efficacy and toxicity. Voriconazole levels should be drawn 12 hours after the last dose after the patient has received at least 5-7 days of consistent voriconazole therapy. The aim of this study was to exclude a significant alteration in voriconazole pharmacokinetics in critically ill patients undergoing continuous venovenous hemofiltration (CVVH). Therapeutic drug monitoring (TDM) of antifungal agents is important in achieving optimal clinical outcomes for those agents that exhibit unpredictable pharmacokinetic behavior and have a narrow therapeutic index with established thresholds for efficacy and toxicity. Previous studies of voriconazole therapeutic drug monitoring (TDM) have suggested concentration monitoring to be clinically useful but have been limited by small patient samples at a single institution. In addition, the most recent evidence examining the relationship between serum concentrations of voriconazole and posaconazole and their efficacy or toxicities was evaluated. This is the first study of voriconazole pharmacokinetics and safety in cirrhosis patients. The pharmacokinetics of voriconazole are influenced by various inter and intrapersonal factors, and for certain populations, such as geriatric patients and pediatric patients, these influences must be considered. study of voriconazole pharmacokinetics and therapeutic drug monitoring. 1,2,3 The drug is metabolized … Voriconazole has non-linear pharmacokinetics and, as substrate and inhibitor of cytochrome P450, it undergoes extensive hepatic metabolism that depends on age, genetic factors, and interactions with other drugs, which may lead to enhanced toxicity of the concomitant medication(s) or ineffective antifungal treatment. Large interindividual and intraindividual variability in drug exposure have been reported 6 . Although voriconazole may be associated with many adverse events, hyponatremia has been rarely reported which potentially could result in death. ell transplant recipients receiving voriconazole were included in this observational study. doi: 10.1128/AAC.00626-12 At 14 mg/kg, of influence to the pharmacokinetic profile of voriconazole, plasma trough concentrations were high enough to result in justifying the need for therapeutic drug monitoring to … 15 Voriconazole is the drug of choice for CNS aspergillosis. (1, 2). Patients <19 years from two pediatric hematologic-oncology wards were retrospectively identified based on unexplained high voriconazole trough concentrations (Cmin > 6 mg/l). A relationship ( P < 0.025) between disease progression and drug concentration was detected. Antimicrob Agents Chemother. 2012 ;56: 4793 - 4799 . 4. Voriconazole (VRC), a triazole agent is extensively metabolized by CYP2C19, CYP2C9, and to a lesser extent, by CYP3A4.